Goldman Sachs
CHRS icon

Goldman Sachs’s Coherus Oncology CHRS Stock Holding History

Goldman Sachs’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
696,158
+389,021
+127% +$691K ﹤0.01% 4978
2025
Q4 		$436K Sell
307,137
-75,643
-20% -$110K ﹤0.01% 5676
2025
Q3 		$628K Buy
382,780
+51,663
+16% +$57.5K ﹤0.01% 5358
2025
Q2 		$242K Sell
331,117
-216,590
-40% -$187K ﹤0.01% 5564
2025
Q1 		$442K Buy
547,707
+12,997
+2% +$15K ﹤0.01% 5259
2024
Q4 		$738K Sell
534,710
-1,542,933
-74% -$1.73M ﹤0.01% 5028
2024
Q3 		$2.16M Sell
2,077,643
-82,388
-4% -$113K ﹤0.01% 4093
2024
Q2 		$3.74M Buy
2,160,031
+445,457
+26% +$896K ﹤0.01% 3427
2024
Q1 		$4.1M Buy
1,714,574
+876,999
+105% +$2.16M ﹤0.01% 3283
2023
Q4 		$2.79M Sell
837,575
-484,186
-37% -$1.3M ﹤0.01% 3661
2023
Q3 		$4.94M Buy
1,321,761
+797,200
+152% +$3.68M ﹤0.01% 2985
2023
Q2 		$2.24M Sell
524,561
-152,469
-23% -$900K ﹤0.01% 3793
2023
Q1 		$4.63M Sell
677,030
-24,562
-4% -$191K ﹤0.01% 3137
2022
Q4 		$5.56M Sell
701,592
-70,630
-9% -$543K ﹤0.01% 3068
2022
Q3 		$7.42M Buy
772,222
+171,247
+28% +$1.73M ﹤0.01% 2785
2022
Q2 		$4.35M Buy
600,975
+126,316
+27% +$1.1M ﹤0.01% 3267
2022
Q1 		$6.13M Sell
474,659
-88,577
-16% -$1.13M ﹤0.01% 3161
2021
Q4 		$8.99M Sell
563,236
-89,250
-14% -$1.56M ﹤0.01% 2872
2021
Q3 		$10.5M Buy
652,486
+76,501
+13% +$1.12M ﹤0.01% 2681
2021
Q2 		$7.97M Sell
575,985
-758,218
-57% -$10.7M ﹤0.01% 2908
2021
Q1 		$19.5M Sell
1,334,203
-94,874
-7% -$1.61M ﹤0.01% 1949
2020
Q4 		$24.8M Sell
1,429,077
-36,387
-2% -$648K 0.01% 1675
2020
Q3 		$26.9M Buy
1,465,464
+174,922
+14% +$3.25M 0.01% 1503
2020
Q2 		$23M Sell
1,290,542
-220,027
-15% -$3.72M 0.01% 1565
2020
Q1 		$24.5M Buy
1,510,569
+95,780
+7% +$1.77M 0.01% 1364
2019
Q4 		$25.5M Buy
1,414,789
+425,484
+43% +$7.85M 0.01% 1658
2019
Q3 		$20M Buy
989,305
+467,766
+90% +$9.35M 0.01% 1780
2019
Q2 		$11.5M Sell
521,539
-109,724
-17% -$1.91M ﹤0.01% 2257
2019
Q1 		$8.61M Buy
631,263
+200,537
+47% +$2.68M ﹤0.01% 2540
2018
Q4 		$3.9M Buy
430,726
+73,067
+20% +$845K ﹤0.01% 3089
2018
Q3 		$5.9M Buy
357,659
+99,881
+39% +$1.77M ﹤0.01% 2861
2018
Q2 		$3.61M Sell
257,778
-155,979
-38% -$2.23M ﹤0.01% 3194
2018
Q1 		$4.57M Buy
413,757
+74,277
+22% +$813K ﹤0.01% 2970
2017
Q4 		$2.99M Buy
339,480
+192,883
+132% +$2.06M ﹤0.01% 3449
2017
Q3 		$1.96M Buy
146,597
+5,674
+4% +$75.1K ﹤0.01% 4012
2017
Q2 		$2.02M Sell
140,923
-172
-0.1% -$3.31K ﹤0.01% 3829
2017
Q1 		$2.98M Buy
141,095
+99,548
+240% +$2.45M ﹤0.01% 3371
2016
Q4 		$1.17M Buy
41,547
+11,590
+39% +$324K ﹤0.01% 4312
2016
Q3 		$802K Buy
29,957
+18,907
+171% +$516K ﹤0.01% 4614
2016
Q2 		$187K Buy
11,050
+866
+9% +$16.3K ﹤0.01% 5742
2016
Q1 		$216K Buy
+10,184
New +$167K ﹤0.01% 5545
2015
Q4 		– Sell
-10,083
Closed -$202K – 7154
2015
Q3 		$202K Buy
+10,083
New +$307K ﹤0.01% 6010
2015
Q2 		– Sell
-23,221
Closed -$710K – 7274
2015
Q1 		$710K Buy
+23,221
New +$600K ﹤0.01% 4796

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Goldman Sachs's CHRS Position: Q1 2026 in Review

Goldman Sachs increased its Coherus Oncology (CHRS) stake by 127% in Q1 2026, buying an estimated $691K and bringing the position to 696,158 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4978.

Goldman Sachs first reported a position in CHRS in Q1 2015 and has held it in 43 quarters since. The position peaked at $26.9M in Q3 2020. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Goldman Sachs held 696,158 shares of Coherus Oncology worth $1.18M as of Q1 2026.
  • Goldman Sachs bought 389,021 Coherus Oncology shares in Q1 2026, an estimated $691K.
  • Coherus Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4978 holding.
  • Goldman Sachs first reported a position in Coherus Oncology in Q1 2015 and has held it in 43 quarters since.
  • Goldman Sachs's Coherus Oncology position peaked at $26.9M in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.